92 related articles for article (PubMed ID: 18665746)
1. Is there a qualitative interaction between adjuvant trastuzumab and size of the primary tumor in breast cancer?
Vesely P; Melichar B
Neoplasma; 2008; 55(5):375-80. PubMed ID: 18665746
[TBL] [Abstract][Full Text] [Related]
2. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial.
Gianni L; Dafni U; Gelber RD; Azambuja E; Muehlbauer S; Goldhirsch A; Untch M; Smith I; Baselga J; Jackisch C; Cameron D; Mano M; Pedrini JL; Veronesi A; Mendiola C; Pluzanska A; Semiglazov V; Vrdoljak E; Eckart MJ; Shen Z; Skiadopoulos G; Procter M; Pritchard KI; Piccart-Gebhart MJ; Bell R;
Lancet Oncol; 2011 Mar; 12(3):236-44. PubMed ID: 21354370
[TBL] [Abstract][Full Text] [Related]
3. CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: a retrospective substudy of the HERA trial (BIG 1-01).
Pestalozzi BC; Holmes E; de Azambuja E; Metzger-Filho O; Hogge L; Scullion M; Láng I; Wardley A; Lichinitser M; Sanchez RI; Müller V; Dodwell D; Gelber RD; Piccart-Gebhart MJ; Cameron D
Lancet Oncol; 2013 Mar; 14(3):244-8. PubMed ID: 23414588
[TBL] [Abstract][Full Text] [Related]
4. Adjuvant trastuzumab: a milestone in the treatment of HER-2-positive early breast cancer.
Baselga J; Perez EA; Pienkowski T; Bell R
Oncologist; 2006; 11 Suppl 1():4-12. PubMed ID: 16971734
[TBL] [Abstract][Full Text] [Related]
5. Adjuvant trastuzumab therapy for HER2-positive breast cancer.
Jahanzeb M
Clin Breast Cancer; 2008 Aug; 8(4):324-33. PubMed ID: 18757259
[TBL] [Abstract][Full Text] [Related]
6. Trastuzumab for the treatment of primary breast cancer in HER2-positive women: a single technology appraisal.
Ward S; Pilgrim H; Hind D
Health Technol Assess; 2009 Jun; 13 Suppl 1():1-6. PubMed ID: 19567207
[TBL] [Abstract][Full Text] [Related]
7. Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
Constantinidou A; Smith I
Breast; 2011 Oct; 20 Suppl 3():S158-61. PubMed ID: 22015286
[TBL] [Abstract][Full Text] [Related]
8. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial.
Smith I; Procter M; Gelber RD; Guillaume S; Feyereislova A; Dowsett M; Goldhirsch A; Untch M; Mariani G; Baselga J; Kaufmann M; Cameron D; Bell R; Bergh J; Coleman R; Wardley A; Harbeck N; Lopez RI; Mallmann P; Gelmon K; Wilcken N; Wist E; Sánchez Rovira P; Piccart-Gebhart MJ;
Lancet; 2007 Jan; 369(9555):29-36. PubMed ID: 17208639
[TBL] [Abstract][Full Text] [Related]
9. Multifactorial central nervous system recurrence susceptibility in patients with HER2-positive breast cancer: epidemiological and clinical data from a population-based cancer registry study.
Musolino A; Ciccolallo L; Panebianco M; Fontana E; Zanoni D; Bozzetti C; Michiara M; Silini EM; Ardizzoni A
Cancer; 2011 May; 117(9):1837-46. PubMed ID: 21509760
[TBL] [Abstract][Full Text] [Related]
10. [Chinese HER2 positive early breast cancer trastuzumab adjuvant therapy: preliminary outcomes].
Zhang P; Yu SY; Shen ZZ; Song ST; Guan ZZ; Jiao SC; Zheng S; Xu GW; Feng FY
Zhonghua Yi Xue Za Zhi; 2012 Dec; 92(47):3345-9. PubMed ID: 23328596
[TBL] [Abstract][Full Text] [Related]
11. Adjuvant trastuzumab with chemotherapy is effective in women with small, node-negative, HER2-positive breast cancer.
McArthur HL; Mahoney KM; Morris PG; Patil S; Jacks LM; Howard J; Norton L; Hudis CA
Cancer; 2011 Dec; 117(24):5461-8. PubMed ID: 21681735
[TBL] [Abstract][Full Text] [Related]
12. Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma.
Bendell JC; Domchek SM; Burstein HJ; Harris L; Younger J; Kuter I; Bunnell C; Rue M; Gelman R; Winer E
Cancer; 2003 Jun; 97(12):2972-7. PubMed ID: 12784331
[TBL] [Abstract][Full Text] [Related]
13. [Very small breast cancer, HER2 positive, and trastuzumab in adjuvant treatment].
Vyzula R
Klin Onkol; 2010; 23(1):21-4. PubMed ID: 20192070
[TBL] [Abstract][Full Text] [Related]
14. [Adjuvant therapy with trastuzumab (Herceptin) in primary breast cancer].
Huober J; Jackisch C; Untch M; Möbus V; Wallwiener D; Kaufmann M; Minkwitz G
Zentralbl Gynakol; 2006 Feb; 128(1):30-7. PubMed ID: 16450285
[TBL] [Abstract][Full Text] [Related]
15. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
16. Human epidermal growth factor receptor 2-positive breast cancer and central nervous system metastases.
Leyland-Jones B
J Clin Oncol; 2009 Nov; 27(31):5278-86. PubMed ID: 19770385
[TBL] [Abstract][Full Text] [Related]
17. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
[TBL] [Abstract][Full Text] [Related]
18. Trastuzumab-based neoadjuvant therapy in patients with HER2-positive breast cancer.
Chang HR
Cancer; 2010 Jun; 116(12):2856-67. PubMed ID: 20564392
[TBL] [Abstract][Full Text] [Related]
19. [Cost-effectiveness of trastuzumab in the treatment of early stages breast cancer patients, in Portugal].
Macedo A; Monteiro I; Andrade S; Cirrincione A; Ray J
Acta Med Port; 2010; 23(3):475-82. PubMed ID: 20654267
[TBL] [Abstract][Full Text] [Related]
20. Cardiotoxicity and incidence of brain metastases after adjuvant trastuzumab for early breast cancer: the dark side of the moon? A meta-analysis of the randomized trials.
Bria E; Cuppone F; Fornier M; Nisticò C; Carlini P; Milella M; Sperduti I; Terzoli E; Cognetti F; Giannarelli D
Breast Cancer Res Treat; 2008 May; 109(2):231-9. PubMed ID: 17638068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]